Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2010

01-08-2010 | Original Article

Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial

Authors: Rudolph M. Navari, Marie C. Brenner

Published in: Supportive Care in Cancer | Issue 8/2010

Login to get access

Abstract

Purpose

The purpose of the study was to determine the effectiveness of megestrol acetate (MA) and olanzapine (OLN) for the treatment of cancer-related anorexia (CRA).

Methods

Eighty adult patients with advanced gastrointestinal cancer or lung cancer (stages III and IV) with CRA (loss of appetite and greater than or equal to 5% loss of preillness stable weight) were randomized to receive daily MA or MA plus OLN for a period of 8 weeks. Patients were assessed weekly using the M.D. Anderson Symptom Inventory with specific measurement of weight, appetite, nausea, and quality of life (QOL) measures.

Results

For the 37 patients receiving MA, 15 patients had a greater than or equal to 5% weight gain, 2 patients had an appetite improvement, 3 patients had an improvement in nausea, and 5 patients had an improvement in QOL at both 4 and 8 weeks. For the 39 patients receiving MA plus OLN, 33 patients had a greater than or equal to 5% weight gain, 25 patients had an appetite improvement, 21 patients had an improvement in nausea, and 23 patients had an improvement in QOL at both 4 and 8 weeks, and there was an improvement in general activity, mood, work, walking, and enjoyment at 8 weeks. There were no grade III or IV treatment-related toxicities in patients receiving MA or the combination of MA plus OLN.

Conclusions

The combination of MA and OLN appears to be an effective intervention for patients with CRA.
Literature
1.
Sarhil N, Mahmoud F, Walsh D et al (2003) Evaluation of nutrition status in advanced metastatic cancer. Support Care Cancer 11:652–659CrossRef
2.
Tramner JE, Heyland D, Dudgeon D et al (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420–429CrossRef
3.
Jatoi A (2006) Pharmacologic therapy for the cancer anorexia/weight loss syndrome: a data-driven practical approach. J Support Oncol 4:499–502PubMed
4.
Yavuzsen T, Davis MP, Walsh D et al (2005) Systemic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 23:8500–8511CrossRefPubMed
5.
Fearon KCH (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. European J Cancer 44:1124–1132CrossRef
6.
Jatoi A, Kumar S, Sloan JA, Nguyen PL (2003) On appetite and its loss. J Clin Oncol 21(9 suppl):79–81CrossRef
7.
Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96CrossRefPubMed
8.
Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine. Eur J Pharmacol 430:341–349CrossRefPubMed
9.
Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22–31PubMed
10.
Hale AS (1997) Olanzapine. Br J Hosp Med 58:443–445
11.
Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438–443PubMed
12.
Parsons B, Allison DB, Loebel A et al (2008) Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 110:103–110CrossRef
13.
Navari RM, Einhorn LH, Loehrer PJ et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529–534CrossRefPubMed
14.
Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291CrossRefPubMed
15.
Passik SD, Lundberg J, Kirsh KL et al (2002) Clinical note: a pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer. J Pain Symptom Manage 23:526–532CrossRefPubMed
16.
Cleland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89:1634–1646CrossRef
17.
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
18.
Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliative Care 6:251–255
19.
Srivastava M, Brito-Delan N, Davis MP et al (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 25:578–582CrossRefPubMed
20.
Thibault R, Goujon N, LeGallic E et al (2009) Use of 10-point analogue scales to estimate dietary intake: a prospective study in patients nutritionally at-risk. Clin Nutr 28:134–140CrossRefPubMed
21.
Woods CA, Cumming B (2009) The impact of test medium on use of visual analogue scales. Eye Contact Lens 35:6–10CrossRefPubMed
Metadata
Title
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial
Authors
Rudolph M. Navari
Marie C. Brenner
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 8/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0739-7

Other articles of this Issue 8/2010

Supportive Care in Cancer 8/2010 Go to the issue

Editorial

Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities

Original Article

What do palliative care patients and their relatives think about research in palliative care?—a systematic review

Review Article

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

Events

Special Section: Oral Complications of Cancer Therapies

Review Article

A systematic review of trismus induced by cancer therapies in head and neck cancer patients

Review Article

Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits